Is Precigen, Inc. on the Verge of Breakeven?

Precigen, Inc. is a biopharmaceutical company with a market cap of $1.1b. Analysts expect the company to breakeven around 2 years from now, with a projected profit of $93m in 2027. To achieve this, the company must grow 69% year-on-year, on average. The company has negative equity on its balance sheet, but this is not uncommon in the biotech industry.